Skip to content
value.today

Damora Therapeutics, Inc.

DMRA
$1.3 Bmarket cap on Oct 26, 2026+6771.4% since Jan 2024
Compare
World rank
#8,102
Revenue
—
For year ending December-2025
Net income
$-210 M
SEC filing
Employees
—

Damora Therapeutics, Inc. in brief

Damora Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Denmark. Its market value was $1.3 B on 26 October 2026, which makes it the 8,102nd largest listed company in the world and the 39th largest in Denmark on this site. Its shares trade under the symbol DMRA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Damora Therapeutics, Inc.

We are a biopharmaceutical company developing therapies for the treatment of hematologic disorders. In our previously announced Asset Acquisition (as defined below), we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms, a group of related, chronic disorders of the bone marrow. Our lead product candidate, DMR-001, targets mutant forms of the calcium binding protein calreticulin, which are collectively known as mutCALR. We have exercised our Option to license exclusive worldwide development and commercialization rights to DMR-001 from Paragon Therapeutics, Inc., pursuant to the Antibody Discovery and Option Agreement, dated as of October 7, 2025, by and among Paragon, Paramora Holding LLC and Pre-Acquisition Damora (as defined below). We intend to develop DMR-001 for the treatment of essential thrombocythemia, an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. Approximately 25% and 35% of cases of ET and MF, respectively, are caused by mutCALR rather than mutations in Janus-associated kinase 2. In contrast to marketed therapies for ET and MF, DMR-001 is designed to selectively target cells that express mutCALR while avoiding the adverse effects associated with non-specific cytoreductive drugs. Furthermore, DMR-001 was designed to have increased affinity, potency and a prolonged half-life when compared with other antibodies in development that target mutCALR. We believe that the potential combination of increased clinical activity and improved pharmacokinetics of DMR-001 positions it as a potential best-in-class therapy for ET and MF. We also have the option to license exclusive worldwide development and commercialization rights from Paragon of two other mutCALR-targeting product candidates, DMR-002 and DMR-003, pursuant to the Paragon Option Agreement.

Damora Therapeutics, Inc. timeline

4 events, 2020–2026
  1. 2020
  2. 🔔
    · approximate
    Initial public offering on Nasdaq
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 🔔
    Initial public offering as Galecto Inc.
    Final prospectus filed with the SEC on 30 October 2020; shares registered for exchange trading on 23 October 2020.
  5. 2026
  6. ✎
    Renamed Damora Therapeutics, Inc.
    Formerly Galecto Inc..

Events of Damora Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$470 M$940 M$1.4 B$1.9 B202120222023202420252026

World rank over time

▲ up 5,316 places since 2021
2021-01-01: #13435#13,43520212022-01-07: #24691#24,69120222022-12-25: #27691#27,69120222023-07-30: #23015#23,01520232024-01-05: #29190#29,19020242026-03-08: #3138#3,13820262026-10-09: #8262#8,26220262026-10-26: #8119#8,1192026

Rank in Denmark: #60 (Jan 2021) · #97 (Jan 2022) · #110 (Dec 2022) · #91 (Jul 2023) · #123 (Jan 2024) · #1 (Mar 2026) · #40 (Oct 2026) · #39 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
5.5×
Free cash flow yield
-3.3%
Net margin
—
Operating margin
—
Return on equity
-87.8%
Liabilities / assets
7.7%
Payout ratio
0.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-37M—FY19Fiscal year ending Dec 2020: revenue —, net income $-35M—FY20Fiscal year ending Dec 2021: revenue —, net income $-52M—FY21Fiscal year ending Dec 2022: revenue —, net income $-62M—FY22Fiscal year ending Dec 2023: revenue —, net income $-38M—FY23Fiscal year ending Dec 2024: revenue —, net income $-21M—FY24Fiscal year ending Dec 2025: revenue —, net income $-210M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-211M$-210M—
Dec 2024——$-22M$-21M—
Dec 2023——$-40M$-38M—
Dec 2022——$-61M$-62M—
Dec 2021——$-52M$-52M—
Dec 2020——$-34M$-35M—
Dec 2019——$39M$-37M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-7M——$3.98$0.00
Dec 2024$-19M——$-18.53$0.00
Dec 2023$-37M——$-36.08—
Dec 2022$-43M$0M$-43M$-2.43—
Dec 2021$-52M$0M$-53M$-2.05$0.00
Dec 2020$-38M——$-7.62$0.00
Dec 2019$-19M——$-161.82—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-7M—Dec ’24Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-201M—Dec ’25Three months to Mar 2026: revenue —, net income $-28M—Mar ’26Three months to Jun 2026: revenue —, net income $-31M—Jun ’26Three months to Sep 2026: revenue —, net income $-32M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Damora Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-211 M
Net income
$-210 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$261 M
Total liabilities
$20 M
Total equity
$239 M

As of December-2025

Top 100 institutional investors in Damora Therapeutics, Inc.#

As of Sep 30, 2026
111 institutions held 59.4 M shares (about 95.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 63.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Damora Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1FMR LLC9,549,056New15.43%$203 MNov 10, 2026
2Fairmount Funds Management LLC8,713,000New14.07%$185 MNov 16, 2026
3Avoro Capital Advisors LLC3,783,000New6.11%$81 MNov 16, 2026
4Venrock Adviser, LLC3,603,595New5.82%$77 MNov 16, 2026
5BlackRock, Inc.3,514,573New5.68%$75 MNov 13, 2026
6Ra Capital Management, L.P.2,399,702New3.88%$51 MNov 16, 2026
7Remedium Capital Partners, LLC2,045,473New3.30%$44 MNov 13, 2026
8Commodore Capital LP1,939,000New3.13%$41 MNov 16, 2026
9Bellevue Group AG1,919,383New3.10%$41 MNov 16, 2026
10Jpmorgan Chase & Co1,872,628New3.02%$40 MNov 12, 2026
11State Street Corp1,780,897New2.88%$38 MNov 12, 2026
12Braidwell LP1,747,659New2.82%$37 MNov 16, 2026
13Viking Global Investors LP1,207,985New1.95%$26 MNov 16, 2026
14Geode Capital Management, LLC1,203,286New1.94%$26 MNov 6, 2026
15UBS Group AG1,082,845New1.75%$23 MNov 10, 2026
16Blackstone Inc.1,035,122New1.67%$22 MNov 16, 2026
17Balyasny Asset Management L.P.973,000New1.57%$21 MNov 16, 2026
18Siren, L.L.C.900,000New1.45%$19 MNov 12, 2026
19Cormorant Asset Management, LP800,000New1.29%$17 MNov 16, 2026
20Vanguard Capital Management LLC557,495New0.90%$12 MNov 13, 2026
21Stempoint Capital LP506,067New0.82%$11 MNov 16, 2026
22Ameriprise Financial Inc474,449New0.77%$10 MNov 16, 2026
23Charles Schwab Investment Management Inc441,650New0.71%$9 MNov 16, 2026
24Adage Capital Partners GP, L.L.C.400,000New0.65%$9 MNov 16, 2026
25Northern Trust Corp397,907New0.64%$8 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Damora Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vestal Point Capital, LP395,000New0.64%$8 MNov 16, 2026
27Citadel Advisors LLC388,042New0.63%$8 MNov 16, 2026
28Vanguard Portfolio Management LLC375,677New0.61%$8 MNov 13, 2026
29Affinity Asset Advisors, LLC375,000New0.61%$8 MNov 13, 2026
30Goldman Sachs Group Inc316,509New0.51%$7 MNov 16, 2026
31Vanguard Fiduciary Trust Co304,507New0.49%$6 MNov 13, 2026
32Seven Fleet Capital Management LP288,439New0.47%$6 MNov 16, 2026
33Perceptive Advisors LLC282,524New0.46%$6 MNov 16, 2026
34ADAR1 Capital Management, LLC281,000New0.45%$6 MNov 16, 2026
35Nantahala Capital Management, LLC278,000New0.45%$6 MNov 13, 2026
36Ikarian Capital, LLC275,710New0.45%$6 MNov 16, 2026
37Millennium Management LLC266,211New0.43%$6 MNov 16, 2026
38Marshall Wace, LLP223,853New0.36%$5 MNov 13, 2026
39Jennison Associates LLC212,425New0.34%$5 MNov 16, 2026
40Bank Of Montreal /can/205,519New0.33%$4 MNov 9, 2026
41Sofinnova Investments, Inc.149,197New0.24%$3 MNov 16, 2026
42PFM Health Sciences, LP144,362New0.23%$3 MNov 16, 2026
43Bank of New York Mellon Corp143,750New0.23%$3 MNov 5, 2026
44Nuveen, LLC141,509New0.23%$3 MNov 10, 2026
45Kalehua Capital Management LLC139,000New0.22%$3 MNov 13, 2026
46DV Equities, LLC130,000New0.21%$3 MNov 16, 2026
47Morgan Stanley95,217New0.15%$2 MNov 13, 2026
48Bank Of America Corp /de/93,188New0.15%$2 MNov 16, 2026
49Boothbay Fund Management, LLC91,261New0.15%$2 MNov 16, 2026
50Rhumbline Advisers63,491New0.10%$1 MNov 10, 2026
51Quadrature Capital Ltd61,463New0.10%$1 MNov 13, 2026
52Alliancebernstein L.P.55,710New0.09%$1 MNov 16, 2026
53Swiss National Bank52,900New0.09%$1 MNov 12, 2026
54Woodline Partners LP51,782New0.08%$1 MNov 16, 2026
55XTX Topco Ltd50,943New0.08%$1 MNov 16, 2026
56Price T Rowe Associates Inc /MD/43,170-5,573 (-11.43%)0.07%$1 MNov 16, 2026
57Squarepoint Ops LLC39,410New0.06%$1 MNov 9, 2026
58Rafferty Asset Management, LLC31,412New0.05%$1 MNov 13, 2026
59California State Teachers Retirement System31,309New0.05%$1 MNov 13, 2026
60UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC31,139New0.05%$1 MNov 16, 2026
61BNP Paribas Financial Markets30,431New0.05%$1 MNov 12, 2026
62Invesco Ltd.28,050New0.05%$1 MNov 12, 2026
63MetLife Investment Management, LLC26,976New0.04%$1 MNov 16, 2026
64MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.25,006New0.04%$1 MNov 16, 2026
65Aquatic Capital Management LLC24,556New0.04%$1 MNov 16, 2026
66VANGUARD ASSET MANAGEMENT, Ltd19,515New0.03%$0 MNov 13, 2026
67Vanguard Global Advisers, LLC19,043New0.03%$0 MNov 13, 2026
68New York State Common Retirement Fund18,800New0.03%$0 MNov 17, 2026
69Quantinno Capital Management LP17,277New0.03%$0 MNov 13, 2026
70Optimize Financial Inc.16,023New0.03%$0 MNov 12, 2026
71Citigroup Inc15,854New0.03%$0 MNov 4, 2026
72Virtus Investment Advisers, LLC15,271New0.02%$0 MNov 12, 2026
73Corient Private Wealth LP13,798New0.02%$0 MNov 16, 2026
74Police & Firemen's Retirement System of New Jersey12,955New0.02%$0 MNov 9, 2026
75Strs Ohio12,800New0.02%$0 MOct 30, 2026
76Wells Fargo & Company/mn12,743New0.02%$0 MNov 16, 2026
77Two Sigma Investments, LP11,873New0.02%$0 MNov 16, 2026
78Profund Advisors LLC11,573New0.02%$0 MOct 29, 2026
79Susquehanna International Group, LLP10,939New0.02%$0 MNov 16, 2026
80Zurcher Kantonalbank (Zurich Cantonalbank)10,582New0.02%$0 MNov 10, 2026
81State Of Wisconsin Investment Board10,429New0.02%$0 MNov 16, 2026
82SEI Investments Co9,921New0.02%$0 MNov 10, 2026
83KLP Kapitalforvaltning As9,700New0.02%$0 MNov 10, 2026
84Vanguard Investments Australia, Ltd.9,279New0.01%$0 MNov 13, 2026
85Persistent Asset Partners Ltd8,625New0.01%$0 MNov 13, 2026
86Legal & General Group Plc5,280New0.01%$0 MNov 16, 2026
87Royal Bank Of Canada2,509New0.00%$0 MNov 16, 2026
88Tower Research Capital LLC (TRC)2,452New0.00%$0 MNov 16, 2026
89Vestcor Inc1,984New0.00%$0 MNov 12, 2026
90China Universal Asset Management Co., Ltd.1,600New0.00%$0 MOct 28, 2026
91State of Wyoming1,363New0.00%$0 MOct 28, 2026
92Sterling Capital Management LLC1,359New0.00%$0 MOct 22, 2026
93Rockefeller Capital Management L.P.577New0.00%$0 MNov 13, 2026
94Global Retirement Partners, LLC191New0.00%$0 MNov 10, 2026
95GAMMA Investing LLC91New0.00%$0 MOct 8, 2026
96Parkside Financial Bank & Trust70New0.00%$0 MOct 27, 2026
97Harbour Investments, Inc.400 (0.00%)0.00%$0 MNov 9, 2026
98Farther Finance Advisors, LLC40New0.00%$0 MOct 8, 2026
99Osaic Holdings, Inc.39New0.00%$0 MNov 12, 2026
100US Bancorp \de\34New0.00%$0 MNov 5, 2026

All 111 institutional investors, with who bought and sold →

Superinvestors holding Damora Therapeutics, Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding Damora Therapeutics, Inc.#

84 funds hold shares worth $321 M (about 5.7% of the company). Since their previous reports 68 added shares and 0 sold, buying $137 M net.
Mutual funds holding Damora Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC1.83 M$46 M—0.05%+4.0%May 31, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.36 M$35 M—0.04%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC834,040$24 M1.3%0.27%no changeJul 31, 2026
🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc.741,346$19 M—0.74%newJun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.714,931$19 M—0.17%+662%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC583,679$17 M0.94%0.05%newJul 31, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC535,388$13 M—0.05%+2.6%May 31, 2026
🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC500,000$12 M—0.22%no changeMay 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC410,184$12 M0.66%0.26%no changeJul 31, 2026
🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC403,200$12 M0.65%0.16%no changeJul 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC454,559$11 M—0.21%no changeMay 31, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC452,806$11 M—0.05%+4.2%May 31, 2026
🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC308,400$9 M0.50%0.19%no changeJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors339,291$9 M—0.06%newJun 30, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC298,142$9 M0.48%0.39%no changeJul 31, 2026
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC280,000$8 M0.45%0.26%no changeJul 31, 2026
🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc.238,497$6 M—0.37%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.212,658$6 M—<0.01%+5.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors154,350$4 M—0.03%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.129,635$4 M0.21%0.05%newJul 31, 2026
🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC118,000$3 M—0.27%no changeJun 30, 2026
🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC105,500$3 M—<0.01%no changeJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC95,134$2 M—0.04%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC93,464$2 M—<0.01%+13%May 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I78,833$2 M—0.15%newMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC65,690$2 M0.11%0.05%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC57,671$2 M—0.04%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC40,687$1 M0.07%<0.01%newJul 31, 2026
🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC37,030$1 M0.06%0.07%+1.9%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation37,900$1 M—0.04%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC36,683$1 M—<0.01%newMay 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC34,442$1 M—0.06%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC33,695$1 M—<0.01%+14%May 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC31,640$1 M—0.04%newJun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC31,560$1 M—<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC25,558$1 M0.04%0.05%newJul 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC24,293$1 M0.04%0.14%+344%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.26,962$1 M—0.04%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC27,510$1 M—<0.01%+18%May 31, 2026
🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC23,800$1 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC23,261$1 M—0.03%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC19,170$0 M—0.02%newJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC17,196$0 M0.03%0.02%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.18,200$0 M—0.02%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC17,856$0 M—0.04%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC16,733$0 M—0.04%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC16,469$0 M—<0.01%newMay 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC15,278$0 M—0.04%newJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors13,967$0 M—<0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.12,500$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Series Opportunistic Insights FundFidelity Management & Research Company LLC12,800$0 M—<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS11,790$0 M—0.04%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC10,752$0 M—0.04%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,376$0 M0.02%0.02%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.8,166$0 M—0.04%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.8,143$0 M0.01%0.04%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC7,185$0 M—0.04%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC5,929$0 M<0.01%0.05%newJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC6,483$0 M—0.04%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors6,223$0 M—<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.5,305$0 M<0.01%0.02%newJul 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,553$0 M—0.03%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS4,710$0 M<0.01%0.05%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,845$0 M—0.04%newJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC3,954$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.4,323$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC4,262$0 M—0.04%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC3,578$0 M—0.04%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,204$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC3,349$0 M—0.06%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC2,600$0 M—0.01%newJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC2,319$0 M—<0.01%newJun 30, 2026
🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors2,013$0 M<0.01%0.02%newJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,869$0 M—0.02%newJun 30, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC1,693$0 M—0.02%—Apr 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC1,392$0 M—0.03%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,348$0 M—<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,206$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,076$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC1,017$0 M—<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC942$0 M—<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC794$0 M—<0.01%newJun 30, 2026
🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC717$0 M—<0.01%newJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.167$0 M—<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 84 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Damora Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$253 K
1 purchase, 1 insider
Sold, 12 months
$31 K
4 sales, 3 insiders
Net, 12 months
$222 K
open market only
Insiders on file
21
since
$253 K-$23 K$0Jan 2025: bought $0 (0 trades), sold $12 K (3 trades)Jan 25Jul 2025: bought $0 (0 trades), sold $4 K (3 trades)JulJan 2026: bought $0 (0 trades), sold $23 K (3 trades)Jan 26Jul 2026: bought $0 (0 trades), sold $7 K (1 trades)JulSep 2026: bought $253 K (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Damora Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jennifer JarrettDirector, President and CEO, DirectorBuy+12,500$20.23$253 K512,500Form 4
filed Garrett WinslowGeneral CounselSell-245$29.98$7 K2,289Form 4
filed Garrett WinslowGeneral CounselOption exercise+680——2,534Form 4
filed Jennifer JarrettSee Remarks, DirectorGrant or award+500,000——500,000Form 4
filed Fairmount Healthcare Fund II L.P.10% ownerOption exerciseindirect+5.81 M——5.81 MForm 4
filed Julianne BrunoDirectorOption exercise+129,000——137,032Form 4
filed Fairmount Healthcare Fund II L.P.10% ownerOption exerciseindirect+2.90 M——2.90 MForm 4
filed Sherwin SattarzadehChief Operating OfficerGrant or award+190,376——190,376Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Damora Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
4.7 M
10.66 days to cover
Dividend per share, Q1 2026
$0.000
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split

Damora Therapeutics, Inc. dividends per share by quarter
Dividend, quarterPer share
Q1 2026$0.000

Trading halts

  • 2025-11-12 14:56 UTC, code LUDP, resumed 15:01 UTC
  • 2025-11-11 19:42 UTC, code LUDP, resumed 19:47 UTC
  • 2025-11-11 19:10 UTC, code LUDP, resumed 19:20 UTC
  • 2025-11-10 15:23 UTC, code LUDP, resumed 15:28 UTC
  • 2025-11-10 15:12 UTC, code LUDP, resumed 15:22 UTC

Fails to deliver

  • : 147 shares at $21.09
  • : 2,173 shares at $21.53
  • : 36,631 shares at $18.44
  • : 329 shares at $18.43
  • : 333 shares at $20.56

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Damora Therapeutics, Inc. scorecard#

Passes 2 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median5.5×Price to book 5.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-3.3%Free cash flow is -3.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year3.98 vs -18.53Diluted EPS 3.98 in fiscal 2025 against -18.53 the year before (report's currency).
    • ✗Net income higher than five years earlier-$210 M-$210 M in fiscal 2025 against -$35 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$210 MNet income -$210 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-165.6%-165.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities13.0×Current ratio 12.98 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 2
    • ✗Pays a dividendNoNo dividends in fiscal 2025.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year17.8%Diluted shares up 17.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Damora Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Damora Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Research and development276.42448382520
General and administrative9.7101313149.02.4
Operating expenses211224061523439
Operating income−211−22−40−61−52−34r39
Net interest income1.20.81.70.70.2——
Other non-operating income (expense)1.10.91.6−0.40.5−1.22.5
Income before tax−210−21−38−62−52−35−37
Income tax0.10.000000
Net income including minority interests−210−21−38−62−52−35−37
Net income attributable to shareholders−210−21−38−62−52−35−37
Earnings per share, basic3.98-18.53-36.08r-2.43-2.05-7.62-161.82
Earnings per share, diluted3.98-18.53-36.08r-2.43-2.05-7.62-161.82
Shares, weighted average (basic)1.41.21.1r2525——
Shares, weighted average (diluted)1.41.21.1r25254.60.3
Dividends per share0.000.00——0.000.00—
Balance sheet
Cash and cash equivalents2581421336316411
Short-term investments0—122738——
Other current assets2.82.73.63.79.95.75.1
Current assets26017376411016956
Property, plant and equipment0.00.10.10.40.2——
Right-of-use (leased) assets0.10.10.20.80.80.90.3
Total assets26117387312217257
Accounts payable0.40.41.73.41.52.93.3
Current liabilities201.25.8114.55.67.9
Lease liabilities (non-current)0.10.10.10.30.40.50.2
Total liabilities201.35.9115.06.18.1
Retained earnings−487−278−256−218−156−104−70
Shareholders' equity239r14r3262117165−71
Total liabilities and equity26117387312217257
Shares outstanding1.61.31.1r2625250.3
Cash-flow statement
Share-based compensation1.03.25.45.64.51.0—
Cash from operating activities−6.7−19−37−43−52−38−19
Capital expenditure———−0.2−0.2——
Acquisitions, net of cash acquired−17—————−0.3
Cash from investing activities−17122212−48—−0.3
Shares issued——2.90.5———
Cash from financing activities267—2.90.5—187—
Exchange-rate effect on cash0.7−0.30.40.3−0.93.10.0
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Damora Therapeutics, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 5 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (3 countries)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.
Damora Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇩🇰 DenmarkHeadquarters1 subsidiary—
🇺🇸 USA1 office3 subsidiaries—
🇸🇪 Sweden1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Damora Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.3 M
Hans T. Schambye, M.D., Ph.D.
Other top executives, average
$709 K
the CEO earned 1.8× this
$100 invested is now
$128
Damora Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Hans T. Schambye, M.D., Ph.D.$1.3 M$2.1 M$709 K$128
2024Hans T. Schambye, M.D., Ph.D.$1.4 M$1.2 M$760 K$26

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Damora Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 2 · Directors and officers 7 · Material agreement 4 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 7 · Shareholder vote 3 · Results announced 1

Damora Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Directors and officers8-K
Auditor changed8-K
Directors and officers8-K
Bylaws or fiscal year changedResults announced8-K
Material agreement8-K
Directors and officersBylaws or fiscal year changed8-K
Directors and officersUnregistered share sale8-K
Bylaws or fiscal year changed8-K/A
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed8-K
Shareholder vote8-K
Directors and officers8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jul 20, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Damora Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$285 MPrivate placement after listing$250 million to $1 billion48equitySEC
Sep 2020$64 MNo. 1$50 to $250 million42equitySEC
Dec 2019$79 MIssued in a merger or acquisition$50 to $250 million35equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Damora Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
29
2023–2023
Latest
29 people
2023-09-20
Damora Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023········29···29
Damora Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
29 people (70% of workforce)Restructuring planSEC 8-K“In connection therewith, on September 20, 2023, the Board of Directors (the “Board”) of the Company approved a restructuring plan (the “Restructuring Plan”), pursuant to which the …”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss Damora Therapeutics, Inc.#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Mutual funds: 84 funds hold $321 millionautomatic update · Jul 31, 2026

    84 mutual funds in 1 country hold shares of Damora Therapeutics, Inc. worth $321 million, about 5.7% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 68 funds added shares and 0 sold; on balance they bought $137 million. Share splits are not counted as trading.

How Damora Therapeutics, Inc. compares in Biotechnology

  • Market cap$1.3 B · higher than 72% of 726
  • Price / book5.5× · lower than 28% of 534
  • FCF yield-3.3% · higher than 76% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Damora Therapeutics, Inc.🇩🇰$1.3 B———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Damora Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Damora Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Damora Therapeutics, Inc.? Suggest a correction